Gil, Joan
Marques-Pamies, Montserrat
Sampedro, Miguel
Webb, Susan M.
Serra, Guillermo
Salinas, Isabel
Blanco, Alberto
Valassi, Elena
Carrato, Cristina
Picó, Antonio
García-Martínez, Araceli
Martel-Duguech, Luciana
Sardon, Teresa
Simó-Servat, Andreu
Biagetti, Betina
Villabona, Carles
Cámara, Rosa
Fajardo-Montañana, Carmen
Álvarez-Escolá, Cristina
Lamas, Cristina
Alvarez, Clara V.
Bernabéu, Ignacio
Marazuela, Mónica
Jordà, Mireia
Puig-Domingo, Manel
Funding for this research was provided by:
Instituto de Salud Carlos III (PM 15/00027)
Novartis Farmacéutica (REMAH)
Article History
Received: 16 March 2022
Accepted: 13 May 2022
First Online: 28 May 2022
Competing interests
: MPD, MS, SMW, GS, IS, CFM, CL, EV, AP, CP, BB, CV, RC, CF, CVA, CAE, IB and, MM declare to have received funding from Novartis through the REMAH consortium for research purposes, and from Novartis, Ipsen and Pfizer as lecturers. TS was an employee of Anaxomics Biotech S.L. The other authors declared no conflicts of interest.